PMID- 1415370
OWN - NLM
STAT- MEDLINE
DCOM- 19921106
LR  - 20180215
IS  - 0250-8095 (Print)
IS  - 0250-8095 (Linking)
VI  - 12
IP  - 1-2
DP  - 1992
TI  - Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the 
      CAPD cycle.
PG  - 80-5
AB  - The current study focused on the effect of continuous ambulatory peritoneal 
      dialysis (CAPD) dialysate obtained following different intraperitoneal dwell 
      periods on the release of interleukin-6 (IL-6) and tumor necrosis factor-alpha 
      (TNF alpha) from mononuclear leukocytes (PBMC). Aliquots of 5 x 10(6)/ml healthy 
      peripheral PBMC were exposed to fresh or spent CAPD dialysate (10-240 min of 
      intra-peritoneal dwell) and stimulated with Escherichia coli endotoxin (10 
      micrograms/ml, 2h). IL-6 and TNF alpha in cell supernatants were determined by 
      specific enzyme immunoassays. Control PBMC in physiological buffer released 361 
      +/- 70 pg/ml IL-6 and 717 +/- 147 pg/ml TNF alpha (mean +/- SEM, n = 8), whereas 
      exposure to fresh dialysis fluids severely suppressed cytokine release from PBMC 
      (less than 30 pg/ml IL-6 and less than 15 pg/ml TNF alpha). A significant 
      inhibition of IL-6 and TNF alpha release was also observed in PBMC exposed to 
      spent dialysate. The inhibitory capacity of the spent fluids was pronounced with 
      increasing intra-peritoneal dwell time (10 min: 183 +/- 45 pg/ml IL-6 and 538 +/- 
      109 pg/ml TNF alpha; 240 min: 26 +/- 5 pg/ml IL-6 and 105 +/- 30 pg/ml TNF alpha; 
      mean +/- SEM, n = 16). These data indicate that the impairment of cell 
      responsiveness following exposure of PBMC to peritoneal dialysate is not 
      restricted to the unused fluids, but is also observed following intra-peritoneal 
      equilibration. Moreover, our findings suggest the presence of cytokine inhibitory 
      factors in the peritoneal dialysate of CAPD patients which appear to accumulate 
      in the peritoneal effluent during the CAPD cycle.
FAU - Jorres, A
AU  - Jorres A
AD  - Department of Nephrology, University Clinic Rudolf Virchow, 
      Berlin-Charlottenburg, FRG.
FAU - Topley, N
AU  - Topley N
FAU - Steenweg, L
AU  - Steenweg L
FAU - Muller, C
AU  - Muller C
FAU - Kottgen, E
AU  - Kottgen E
FAU - Gahl, G M
AU  - Gahl GM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
RN  - 0 (Dialysis Solutions)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Cells, Cultured
MH  - Dialysis Solutions/*pharmacology
MH  - Humans
MH  - Interleukin-6/*biosynthesis
MH  - Leukocytes, Mononuclear/*drug effects/metabolism
MH  - *Peritoneal Dialysis, Continuous Ambulatory
MH  - Tumor Necrosis Factor-alpha/*biosynthesis
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1159/000168422 [doi]
PST - ppublish
SO  - Am J Nephrol. 1992;12(1-2):80-5. doi: 10.1159/000168422.